Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice

Molecular and Cellular Endocrinology

Volumn 420, Issue , 2016, Pages 37-45

  Millar, P J B ^a   Pathak, V ^a   Moffett, R C ^a   Pathak, N M ^a   Bjourson, A J ^a   O'Kane, M J ^a,b   Flatt, P R ^a   Gault, V A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

Author keywords

Dapagliflozin; Diabetes; Glucose dependent insulinotropic polypeptide (GIP); Insulin secretion; SGLT2 inhibitor

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE BLOOD LEVEL; GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE, ALA(2)-; GLUCOSIDE; INSULIN; MESSENGER RNA; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; DIABETES MELLITUS, EXPERIMENTAL; DIET RESTRICTION; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; LIPID DIET; MALE; METABOLISM; MOUSE; PANCREAS ISLET; PATHOLOGY;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; ENERGY METABOLISM; FASTING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSIDES; HOMEOSTASIS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; RNA, MESSENGER; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84949009661     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.11.019     Document Type: Article

References (40)

1. ATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2009, 94:603-608.
2. Ahrén B. Glucagon - early breakthroughs and recent discoveries. Peptides 2015, 67:74-81.
3. Bailey C.J. The current drug treatment landscape for diabetes and perspectives for the future. Clin. Pharmacol. Ther. 2015, 98:170-184.
4. Betteridge D.J. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet. Med. 2011, 28:759-771.
5. Bhat V.K., Kerr B.D., Flatt P.R., Gault V.A. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem. Pharmacol. 2013, 85:1655-1662.
6. Bonner C., Kerr-Conte J., Gmyr V., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 2015, 21:512-517.
7. Deacon C.F., Nauck M.A., Meier J., Hücking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000, 85:3575-3581.
8. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 1993, 138:159-166.
9. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
10. Gault V.A., Flatt P.R., O'Harte F.P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 2003, 308:207-213.
11. Gault V.A., Irwin N., Green B.D., et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005, 54:2436-2446.
12. Gault V.A., Kerr B.D., Harriott P., Flatt P.R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin. Sci. (Lond.) 2011, 121:107-117.
13. Gault V.A., Lennox R., Flatt P.R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes. Metab. 2015, 17:403-413.
14. Han S., Hagan D.L., Taylor J.R., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57:1723-1729.
15. Hediger M.A., Rhoads D.B. Molecular physiology of sodium-glucose cotransporters. Physiol. Rev. 1994, 74:993-1026.
16. Hinke S.A., Gelling R.W., Pederson R.A., et al. Dipeptidyl peptidase IV-resistant [d-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002, 51:652-661.
17. Højberg P.V., Vilsbøll T., Rabøl R., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207.
18. Igoillo-Esteve M., Marselli L., Cunha D.A., et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 2010, 53:1395-1405.
19. Irwin N., Flatt P.R. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Curr. Opin. Pharmacol. 2013, 13:989-995.
20. Islam M.S., Wilson R.D. Experimentally induced rodent models of type 2 diabetes. Methods Mol. Biol. 2012, 933:161-174.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
22. López-Jaramillo P., Gómez-Arbeláez D., López-López J., et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm. Mol. Biol. Clin. Investig. 2014, 18:37-45.
23. Macdonald F.R., Peel J.E., Jones H.B., et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes. Metab. 2010, 12:1004-1012.
24. Martin C.M., Gault V.A., McClean S., Flatt P.R., Irwin N. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25. Biochem. Pharmacol. 2012, 84:312-319.
25. Martin C.M., Irwin N., Flatt P.R., Gault V.A. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores. Biochim. Biophys. Acta 2013, 1830:3407-3413.
26. McClenaghan N.H., Barnett C.R., Ah-Sing E., et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996, 45:1132-1140.
27. Meneilly G.S., Bryer-Ash M., Elahi D. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 1993, 16:110-114.
28. Meng W., Ellsworth B.A., Nirschl A.A., et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2008, 51:1145-1149.
29. Merovci A., Solis-Herrera C., Daniele G., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 2014, 124:509-514.
30. Moffett R.C., Patterson S., Irwin N., Flatt P.R. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Diabetes Metab. Res. Rev. 2015, 31:248-255.
31. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 91:301-307.
32. Pathak V., Vasu S., Flatt P.R., Irwin N. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1, Diabetes Obes. Metab., 2014 Apr, 16(4):357-365. Epub 2013 Nov 20. 10.1111/dom.12227.
33. Piteau S., Olver A., Kim S.J., et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycaemia in the Zucker rat. Biochem. Biophys. Res. Commun. 2007, 362:1007-1012.
34. Saisho Y. Beta-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J. Diabetes 2015, 6:109-124.
35. Sheen A.J., Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 2014, 40:S4-S11.
36. Tahrani A.A., Barnett A.H., Bailey C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013, 2:140-151.
37. Vasu S., Moffett R.C., McCluskey J.T., Hamid M.H., Irwin N., Flatt P.R. Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. Gene Ther. 2013, 20:1077-1084.
38. Wright E.M. Renal Na(+)-glucose cotransporters. Am. J. Physiol. Ren. Physiol. 2001, 280:10-18.
39. Zambrowicz B., Ding Z.M., Ogbaa I., et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycaemic control in type 2 diabetes. Clin. Ther. 2013, 35:273-285.
40. Zhang Q., Ramracheya R., Lahmann C., et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013, 18:871-882.